中国神经再生研究(英文版) ›› 2023, Vol. 18 ›› Issue (5): 996-1003.doi: 10.4103/1673-5374.355748

• 综述:神经损伤修复保护与再生 • 上一篇    下一篇

靶向一氧化氮/cGMP信号通路治疗慢性疼痛

  

  • 出版日期:2023-05-15 发布日期:2022-11-01
  • 基金资助:
    国家自然科学基金(82071556,81873793,82001198,82101310); 国家重点研究发展计划(2020YFC2005300)

Targeting the nitric oxide/cGMP signaling pathway to treat chronic pain

Dan-Yang Li, Shao-Jie Gao, Jia Sun, Long-Qing Zhang, Jia-Yi Wu, Fan-He Song, Dai-Qiang Liu, Ya-Qun Zhou*, Wei Mei*   

  1. Department of Anesthesiology and Pain Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China
  • Online:2023-05-15 Published:2022-11-01
  • Contact: Wei Mei, PhD, wmei@hust.edu.cn; Ya-Qun Zhou, PhD, yqzhou2019@hust.edu.cn.
  • Supported by:
    This work was supported by the National Natural Science Foundation of China, Nos. 82071556 (to WM), 81873793 (to WM), 82001198 (to YQZ), 82101310 (to DQL); the National Key Research and Development Program of China, No. 2020YFC2005300 (to WM).  

摘要:

目前已有研究证实,一氧化氮/环鸟苷3’,5’-单磷酸(cGMP)信号通路在疼痛传递和加工过程中起中介作用,为此,文章就一氧化氮/cGMP信号通路在神经性疼痛、骨癌性疼痛、炎性疼痛和吗啡耐受等慢性疼痛中的作用机制进行综述。①细胞中一氧化氮/cGMP信号通路的主要过程是一氧化氮激活可溶性鸟苷酸环化酶,从而导致后续cGMP的产生,随后cGMP激活cGMP依赖的蛋白激酶,导致多个靶点的激活,如ATP敏感的K+通道的打开。②现有研究证据表明,脊髓一氧化氮/cGMP信号的激活不仅诱导下游分子上调,还诱导反应性星形胶质细胞增生和小胶质细胞极化参与慢性疼痛过程。③在背根神经节神经元中,利钠肽与颗粒鸟苷环化酶结合产生并进一步激活cGMP/蛋白激酶通路也参与了慢性疼痛的发生发展。④在各种疼痛模型中,多个受体上调参与一氧化氮/cGMP信号通路的激活;一氧化氮/cGMP信号通路可诱导下游效应物的表达,在炎症性疼痛中发挥镇痛和镇痛作用。⑤上述研究结果表明,一氧化氮/cGMP信号通路的激活在慢性疼痛的发生发展中起着不可替代的作用,这一具有双重作用的信号通路是探索慢性疼痛有趣且有前景的治疗靶点。

https://orcid.org/0000-0001-6556-6628 (Wei Mei); https://orcid.org/0000-0001-6917-4808 (Ya-Qun Zhou)

关键词: 骨癌疼痛, 慢性疼痛, cGMP, 背根神经节, 炎性疼痛, 吗啡耐受, 神经性疼痛, 一氧化氮, 蛋白激酶G, 脊髓

Abstract: Nitric oxide (NO)/cyclic guanosine 3′,5′-monophosphate (cGMP) signaling has been shown to act as a mediator involved in pain transmission and processing. In this review, we summarize and discuss the mechanisms of the NO/cGMP signaling pathway involved in chronic pain, including neuropathic pain, bone cancer pain, inflammatory pain, and morphine tolerance. The main process in the NO/cGMP signaling pathway in cells involves NO activating soluble guanylate cyclase, which leads to subsequent production of cGMP. cGMP then activates cGMP-dependent protein kinase (PKG), resulting in the activation of multiple targets such as the opening of ATP-sensitive K+ channels. The activation of NO/cGMP signaling in the spinal cord evidently induces upregulation of downstream molecules, as well as reactive astrogliosis and microglial polarization which participate in the process of chronic pain. In dorsal root ganglion neurons, natriuretic peptide binds to particulate guanylyl cyclase, generating and further activating the cGMP/PKG pathway, and it also contributes to the development of chronic pain. Upregulation of multiple receptors is involved in activation of the NO/cGMP signaling pathway in various pain models. Notably the NO/cGMP signaling pathway induces expression of downstream effectors, exerting both algesic and analgesic effects in neuropathic pain and inflammatory pain. These findings suggest that activation of NO/cGMP signaling plays a constituent role in the development of chronic pain, and this signaling pathway with dual effects is an interesting and promising target for chronic pain therapy.

Key words: bone cancer pain, chronic pain, cyclic GMP, dorsal root ganglion, inflammatory pain, morphine tolerance, neuropathic pain, nitric oxide, protein kinase G, spinal cord